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Objective: The anti-inﬂammatory and anti-catabolic effects of neonatal Mesenchymal Stromal Cell (MSC)
were investigated in a xenogeneic model of mild osteoarthritis (OA). The paracrine properties of MSC on
synoviocytes were further investigated in vitro.
Study design: OA was induced by medial meniscal release (MMR) in 30 rabbit knees. A single early (day
3) or delayed (day 15) intra-articular (IA) injection of MSC isolated from equine Umbilical Cord Wharton's
jelly (UC-MSC) was performed. Rabbits were euthanized on days 15 or 56. OA grading was performed and
gene expression of inﬂammatory cytokines and metalloproteinases was measured in synovial tissue.
Paracrine effects of UC-MSC were investigated using UC-conditioned vs control medium on rabbit pri-
mary synoviocytes stimulated with interleukin 1 beta in vitro.
Results: No adverse local or systemic responses were observed clinically after xenogeneic UC-MSC in-
jection. At study end point, cartilage ﬁbrillation was lower in early treatment than in delayed treatment
group. Cellular inﬁltrate was observed in the synovium of both UC-MSC groups. OA synovium exhibited a
reduced expression of metalloproteinases-1, -3, -13 in the early cell-treated group at d56. In vitro,
UC-conditioned medium exerted anti-inﬂammatory and anti-catabolic effects on synoviocytes exposed
to pro-inﬂammatory stimulus.
Conclusions: Early IA injection of equine UC-MSC was effective in preventing OA signs in rabbit knees
following MMR. UC-MSC target the synovium and modulate the gene expression pattern of synoviocytes
to promote an anti-catabolic environment. This conﬁrms the synovium is a major target and mediator of
MSC therapy, modulating the expression of matrix-degrading enzymes.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is characterized by a catabolic and inﬂam-
matory joint environment, leading to progressive cartilage degra-
dation1,2. One of the main challenges in the management of OA is to
dampen local inﬂammation in an attempt to stop the process of
cartilage destruction and relieve pain3,4. The synovial membranes to: C. Boulocher, UPSP
'Etoile, France.
(C. Boulocher).
ternational. Published by Elsevier Lhas attracted much attention, since synovitis is a major contributor
of disease progression by accelerating the catabolism of articular
cartilage5.
In the last decade, accumulating data in preclinical models have
reported promising results with the use of Mesenchymal Stromal
Cells (MSC) for the treatment of joint diseases6. Interestingly, bio-
distribution studies following intra-articular (IA) injection of MSC
have shown that transplanted cells target preferentially the syno-
vial membrane rather than the cartilage itself7,8. These data are in
agreement with recent models showing that the ability of MSC
transplantation as a therapeutic approach for OA rely more on their
paracrine properties than on their chondrogenic differentiation
potential9,10. Upon induction, MSC secrete a variety of solubletd. All rights reserved.
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interact transiently with the microenvironment (the so-called “hit
and run” mechanism)11. Altogether, it suggests that attempting to
regulate the synovial response by the use of MSC could be a valu-
able strategy for OA therapy.
MSC are considered as relatively hypoimmunogenic. Conse-
quently, the number of clinical trials using third-party donor cells
has considerably expanded during the last few years12. In ortho-
pedic medicine, recent preclinical data have conﬁrmed the safety of
injections of allogeneic MSC in dog13 and horse14e17. Furthermore,
accumulating evidences suggest that MSC may also function across
species barriers18. Xenogeneic MSC transplantations have been
used for bone and cartilage regeneration without evidence of
immunological rejection19,20 even if contrasting results have been
reported regarding the efﬁciency of the xenograft to repair critical-
size bone defect21. In addition, recent in vitro data showed that
xenogeneic MSC do not elicit cellular immunoactivation in short-
term co-culture models, suggesting that xenogeneic MSC may be
immunotolerated, at least initially, in a host environment22. Alto-
gether, these data suggest that xenogeneic models could be valu-
able strategies to elucidate preliminary mechanisms, even if
caution should be taken for clinical translation.
The aim of this study was to examine the effect of early and
delayed IA injection of xenogeneic UC-MSC in preventing synovial
inﬂammation and cartilage degradation in a rabbit model of OA. A
relevant dose of equine UC-MSC was administrated by a single IA
injection 3 days (early) or 15 days (delayed) after OA induction by
medial meniscal release (MMR) in rabbits. End-point evaluations
were performed at early (d15) and mild (d56) stages of OA.
Particular attention was paid to the interactions between MSC and
the synovial membrane especially regarding anti-inﬂammatory
and immunomodulatory effects. We extended our ﬁndings by
studying the MSC/synovium interactions in vitro, in order to
decipher mechanisms of action.
Materials and methods
UC-MSC culture and characterization
Equine UC-MSC were provided by Vetbiobank (Marcy l'Etoile,
France). Umbilical cords were recovered from selected mares
belonging to French National Studs (IFCE, Saumur, France)
following parturition, in accordance with standard veterinary
practice. MSC were isolated from Wharton's jelly tissue and
cultured following the laboratory standard procedures. UC-MSC
used for IA and in vitro assays were grown for ﬁve passages.
UC-MSC were characterized by ﬂow cytometry (Accuri C6, BD
Biosciences) using common equine MSC markers23. Cells were
labeled for 20 min at 4C with mouse anti-human CD90-PE, mouse
anti-human CD44-APC, mouse anti-human CD29-PE (all three
purchased from BioLegend), mouse anti-horse MHC1-FITC, mouse
anti-horse MHC2-FITC, mouse anti-human CD105-PE and mouse
anti-human CD45-FITC (all four purchased from ABD Serotec).
Negative control staining was performed with the corresponding
conjugated isotype antibodies. In vitro differentiation potential of
UC-MSC toward osteogenic, adipogenic, and chondrogenic lineages
was evaluated. Brieﬂy, UC-MSC were incubated for 2 weeks with
osteogenic medium consisted of Dulbecco's modiﬁed Eagles me-
dium (DMEM) supplemented with 10% fetal bovine serum (FBS),
50 mM L-ascorbate-2-phosphate, 100 nM dexamethasone and
10 mM b-glycerophosphate. Osteogenic differentiation was evalu-
ated by Alizarin Red S histological staining. To induce adipogenic
differentiation, UC-MSC were exposed to adipogenic medium,
using DMEM supplemented with 15% rabbit serum, 1 mM
dexamethasone and 10 mg/ml insulin (all from SigmaeAldrich). OilRed O staining was used to detect intracytoplasmic lipid droplets.
Chondrogenic differentiation was induced by culturing cells for 2
weeks in chondrogenic medium consisting of high-glucose DMEM
supplemented with 0.1 mM dexamethasone, 50 mg/ml ascorbic acid,
40 mg/ml proline, 1 nM sodium pyruvate, 1% insulin-transferrin-
selenium (ITS) supplement premix, 50 ng/ml bone morphoge-
netic protein 2 (BMP-2; Medtronic BioPharma B.V.) and 10 ng/ml
transforming growth factor beta 1 (TGF-b1; Miltenyi). Proteoglycan
deposits were visualized by Alcian blue staining.Experimental OA model and study design
All work was conducted in full compliance with the ethical
committee guidelines for animal protection and in accordance with
the legislation of the European Community (agreement n 1220).Surgery: MMR
After acclimation and quarantine, experimental OA was surgi-
cally induced in 30 adult female White New Zealand rabbits
(3.5e4.5 kg), housed in individual cages in the Experimental
Medicine and Surgery Center, Claude Bourgelat Institute (ICl-B). A
mini-arthrotomy of the left knee was performed under general
inhalation anesthesia using a medial parapatellar approach under
sterile conditions. MMR was performed by a complete radial
transection of the medial meniscus at mid-body level, just caudal
to the medial collateral ligament. Special care was taken to avoid
iatrogenic injury to ligaments and articular cartilage. Complete
MMR was conﬁrmed by free mobilization of the caudal part of the
medial meniscus. Joint capsule, subcutaneous tissues and skin
were closed layer by layer with continuous sutures and strict
attention to hemostasis. The operated leg was not immobilized
and rabbits were allowed to move freely in their cages. The right
knee was left intact. Clinical and orthopedic examinations were
performed twice weekly. More especially, a careful survey of
general state (vigilance, limb support, hair, wound) was performed
twice a week. In addition, injected joints were scored blindly by a
trained veterinary surgeon from 0 to 3 for swelling, heat, ﬂow at
injection site, palpation and mobilization pain, redness and
hematoma.Study design
Details of the study design are recapitulated in Fig. 1. To inves-
tigate the effect of the timing of cell administration on OA pro-
gression, rabbits were randomly attributed to one of two different
groups depending on the timing of the injection, using R soft-
ware24. Speciﬁcally, a single IA injection of UC-MSC was performed
either on day 3 (early treatment group; n ¼ 14) or on day 15
(delayed treatment group; n ¼ 7) after MMR surgery. Time-
matched control-operated groups receiving only saline were
included (6 control-operated injected at day 3 and 3 control-
operated injected at day 15). The rabbits were chemically
restrained (Ketamine 1000®, 30mg/kg and Domitor®, 80 mg/kg, IM).
The left hindlimb was shaved prior to surgical preparation of skin.
The syringe containing 3,5.106 UC-MSC in 150 mL of phosphate-
buffered saline (PBS) was prepared sterilely and shaken gently
prior to the injection. Animals were sacriﬁced at two time points
during the onset of OA. At day 15, seven rabbits from the early
treatment group and six rabbits from the time-matched control-
operated group were euthanized. At day 56, all other animals
were sacriﬁced. Animals were injected with 5 mL of pentobarbital
(Dolethal®) after being chemically restrained ketamine, 30 mg/kg,
IM (Ketamine 1000®) and medetomidine, 80 mg/kg (Domitor®, IM).
Following euthanasia, tissues were harvested for further analyses.
Fig. 1. Schematic diagram of the study design. At day 0, MMR was performed on the left knee in 30 rabbits. A single IA injection of UC-MSC was performed either on day 3 (early
treatment group; n ¼ 14) or on day 15 (delayed treatment group; n ¼ 7) after MMR surgery. Time-matched control-operated groups receiving only saline were included (six controls
injected at day 3 and three controls injected at day 15). Animals were sacriﬁced at two time points (day 15 or 56) during the OA onset. At day 15, seven rabbits from the early
treatment group and six rabbits from the matched-control group were euthanized. All other animals were sacriﬁced at day 56.
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Gross morphology
Left knees were opened by an incision lateral to the patellar
tendon and were carefully dissected. For osteophyte evaluation,
each marginal osteophyte was scored on a scale 0e3 (absent to
large) at six sites (lateral and medial tibial condyles, lateral and
medial femoral condyles, femoral trochlea and patella). Gross
morphology of the cartilage was evaluated using Visual Analog
Evaluation (VAE) after China ink coloration of the cartilage. The VAE
score consisted of the product of the percentage of the area
involved and a factor based on the grade of the cartilage lesion, as
recommended by the International Cartilage Repair Society (ICRS)
for grading cartilage defects25. An experienced observer scored the
cartilage lesion at the same sites as for the osteophyte score. Gross
morphology of menisci was recorded; particular attentionwas paid
to the sectioned area.
Tissue collection
Synovium was collected from the lateral compartment of knee
joints. Fibrous tissues were carefully removed. Synovial membrane
samples were placed in 10% neutral buffered formalin for histo-
logical analysis. For molecular analysis, in each operated knee, a
small piece of synovial tissue and a sample of cartilage obtained
from just below the popliteus tendon attachment on the medial
femoral condyle were ﬂash-frozen in liquid nitrogen immediately
after collection and stored at 80C for further analysis.
Histological examination of synovial tissue
Histological evaluation of the synoviumwas performed on days
15 and 56. Three sections (4 mm) of each synovial membrane
parafﬁn block were stained with Hematoxylin-eosin-safranin.
Evaluation of synovial tissue included grading of synoviocyte pro-
liferation and hypertrophy, inﬂammatory inﬁltrates, villous hy-
perplasia, proliferation of ﬁbroblasts/ﬁbrocytes, proliferation of
blood vessels, cartilage, bone detritus and hemosiderosis. Histo-
logical sections were scored by Laverty's scoring system26. A blin-
ded experienced observer performed all the histological grading
twice.
Quantitative assessment of tibial cartilage thickness distribution by
equilibrium partitioning of an Ionic Contrast agent via micro-CT
(EPIC-mCT)
Based on results of dilution and incubation time studies, the
dissected proximal tibiae were immersed in a 40%/60% solution of
Hexabrix (320 mg diode/mL)/PBS at room temperature for 30 minthen rinsed in a normal saline solution before scanning. At day 56,
EPIC-mCT scans were performed with a GE Locus eXplore m-CT27.
The proximal tibia was scanned at a 45 mm3 voxel resolution.
Scanning parameters were 80 kV, 450 mA and 2000 ms. A
260*260*100 mm3 Region Of Interest (ROI) was positioned at a
constant location based on anatomical landmarks. An appropriate
threshold was determined visually to perform the cartilage seg-
mentation of the ROI. Three dimensional (3D) modeling
morphology and 3D quantiﬁcation of local cartilage thickness were
obtained for cartilage from the medial tibial plateau using the GE
Micro-View software.
A normal range was obtained by scanning non-operated knee
joints of ten randomized limbs from the study.
Gene expression analysis of synovial tissue and cartilage
RNA isolation; real-time PCR analysis
Frozen synovial membranes and cartilage sections were dis-
rupted in 1 ml of Tri Reagent (Sigma Aldrich) using a Polytron ho-
mogenizer. Following centrifugation, the aqueous phase was then
processed on columns (SV Total RNA kit, Promega) for further RNA
extraction. cDNA synthesis was carried out, using the GoScript
Reverse Transcription System (Promega).
qPCR analysis was then performed using the GoTaq qPCRmaster
mix (Promega) on the Stratagene Thermocycler MX3000. Speciﬁc
primers for each gene of interest were designed and sequences are
reported in Annex 1. Data were normalized to the housekeeping
gene Hypoxanthine-guanine phosophoribosyltransferase (HPRT).
Relative gene expression levels were calculated using the 2DDCt
method28.
In vitro analysis of the paracrine properties of UC-MSC
Accumulating evidence suggests that MSC exert clinical beneﬁts
through paracrine mechanisms9,29. Therefore we tested whether
UC-conditioned medium (medium containing factors secreted by
the UC-MSC) could modulate gene expression of primary expanded
synoviocytes cultivatedunder proinﬂammatory condition (10ng/ml
interleukin 1 beta (IL1-b) for 48 h, as previously described30).
Synoviocytes isolation
The synoviumwas dissected from the knee joints of two healthy
New Zealand White adult rabbits immediately after euthanasia
from unrelated studies. The joint cavity was opened and the
synovium was retrieved from the dorso-medial area of the knee
joint. The tissue was minced into small pieces for primary explant
N. Saulnier et al. / Osteoarthritis and Cartilage 23 (2015) 122e133 125culture. An initial cellular outgrowth was observed following 3e5
days, with medium being renewed every 2 days. Tissue fragments
were removed after 7 days in culture and cells grown until sub-
conﬂuence prior to passaging.
UC-conditioned medium preparation
UC-conditioned media were obtained from two independent
equine UC-MSC cultures grown for 72 h in standard proliferation
conditions. Media were collected, centrifuged for 10 min at 500 g
to remove cellular debris and stored at 80C until further use.
In vitro synoviocytes stimulation
Synoviocytes (passage 2e3) were seeded in 6-well plates. When
reaching 80% conﬂuence, the cells were washed 3 times with PBS
and stimulated with IL-1b (10 ng/ml) (SigmaeAldrich; #I9401)
diluted in control or UC-conditioned medium. Cultures were
incubated for 48 h at 37C. At the end of the treatment, cells were
washed with PBS and re-suspended in RNA lysing solution (SV Total
RNA Isolation System Promega) prior to storage at 80C. Molecular
expression analysis of target genes was further realized, as
described above.
Statistical and graphical analyses
All analyses were performed using R software. Non-parametric
testing was employed for all data, as the sample size was limited.
Comparisons between groups were conducted using the Wilcoxon
test. Signiﬁcance was accepted at P < 0.05.Fig. 2. Representative images of the macroscopic evaluation. (A) Control-operated (d15 pos
(d56 post MMR). (D) Early UC-MSC treatment (d56 post MMR). (D) The crosses indicate the
differences were found in paired comparisons of osteophytic scores between early and delaye
present (ﬁbrillation) on the medial tibial condyle.Results
UC-MSC characterization
UC-MSC were isolated from Wharton's jelly, the connective
tissue surrounding umbilical cord and expanded to form culture of
adherent cells with ﬁbroblastic morphology. UC-MSC were homo-
geneously positive for the common MSC markers, CD90, CD29,
CD44, MHC1, and CD105, while the expression of CD45 and MHC2
was undetectable. Representative ﬂow cytometric proﬁle of the UC-
MSC is illustrated in Annex 2. The tri-lineage differentiation po-
tential of the cells was evaluated in vitro (Annex 3). The ability of
the cells to differentiate toward the osteogenic lineage was evi-
denced by alizarin red staining showing calcium accumulation in
the culture. Under adipogenic culture conditions, UC-MSC accu-
mulated a large amount of lipid droplets in their cytoplasm.
Chondrogenic differentiation assay showed mild Alcian blue
staining of extracellular matrix suggesting glycosaminoglycan
synthesis.
Ex vivo evaluation of OA
Recovery from the surgery was uneventful. No rabbits were
limping after the surgery and surgical wound healed well. No side
effects were observed by clinical examinations neither short term
nor long term after IA injections, conﬁrming the safety of the pro-
cedure. More especially, all rabbits had normal food and water
intake as well as a normal behavior during the study. Clinical eval-
uationof the joints showednodischarge, edema, painatpalpationort MMR). (B) Early UC-MSC treatment (d15 post MMR). (C) Delayed UC-MSC treatment
small osteophytes present at the margin of the medial tibial condyles. No signiﬁcant
d UC-MSC treatment groups. In the early treatment group, cartilage damages were only
Table I
Osteophyte scores at day 15 and at day 56 following MMR
End points Osteophyte scores (mean ± SD)
IA treatments Femoral condyles Tibial condyles Femoral trochlea Patella Global score
MMR (left knee) day 0 (n ¼ 30) Medial Lateral Medial Lateral
Early treatment (n ¼ 7) (UC-MSC day 3) Day 15 0.14 ± 0.38 0.00 ± 0.00 0.14 ± 0.38 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.29 ± 0.49
Control MMR (n ¼ 6) (PBS day 3) 0.33 ± 0.52 0.00 ± 0.00 0.67 ± 0.52 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.00 ± 0.89
Early treatment (n ¼ 7) (UC-MSC day 3) Day 56 0.43 ± 0.79 0.14 ± 0.38 1.14 ± 0.38 0.00 ± 0.00 0.71 ± 0.76 0.00 ± 0.00 2.43 ± 1.40
Delayed treated (n ¼ 7) (UC-MSC day 15) 0.86 ± 0.69 0.14 ± 0.38 1.43 ± 0.98 0.00 ± 0.00 0.71 ± 0.76 0.00 ± 0.00 3.14 ± 1.07
N. Saulnier et al. / Osteoarthritis and Cartilage 23 (2015) 122e133126mobilization during the study. No difference between the groups
was observed regarding knee swelling scores (data not shown).
Gross morphological assessment
Fig. 2 illustrates typical OA lesions of the tibial plate (i.e., where
damages ﬁrst appeared and predominated). As expected in this
model of knee OA without destabilization, gross morphological
score of individual was predominantly comprised of early osteo-
phyte formation, synovial ﬁbrosis and cartilage damage (ﬁbrilla-
tion), which is compatible with early OA lesions at day 15 and mild
OA at day 56. Results are detailed in Tables I and II.
At day 15, healing of the transected meniscus was not observed
in any MMR knees. Small osteophytes were present only in the
medial compartment. Global osteophytic score was not statistically
different between control-operated and early treatment groups.
Medial tibial condyle osteophytic score was lower in the early
treatment group. In all rabbits, cartilage ﬁbrillation was only pre-
sent on the medial tibial condyle. At this site, VAE scores were
signiﬁcantly lower in the early treatment group (11.79 ± 7.32 vs
28.33 ± 9.04; P ¼0.01). Macroscopic changes of synovial membrane
(inﬂammation) were observed in two rabbits out of six in the
control-operated group and one rabbit out of seven in the early
treatment group.
At day 56, healing of the transected meniscus was not observed
in any MMR knees. No signiﬁcant differences were found in paired
comparisons of osteophytic scores between early and delayed UC-
MSC treatment groups. While cartilage damages were present on
both the femoral and tibial condyles in the delayed treatment
group, they were only present (ﬁbrillation) on the medial tibial
condyle in the early treatment group. In addition, VAE scores of this
regionwere signiﬁcantly lower in the early treatment group than in
the delayed treatment group (10 ± 5 vs 30.36 ± 13.57; P ¼ 0.017).
Synovial membrane was thickened in all operated knees.
Histology
Histological evaluation of synovial sections at day 15 high-
lighted cellular inﬁltrates qualiﬁed as “lymphoplasmacytic” in UC-Table II
Visual Analogical Evaluations at day 15 and at day 56 following MMR. The early treatment
control-operated at d15 as well as than delayed treatment group at d56
End points Visual analogical evalu
IA treatments Femoral condyles
MMR (left knee) day 0 (n ¼ 30) Medial Latera
Early treated (n ¼ 7) (UC-MSC day 3) Day 15 0.00 ± 0.00 0.00 ±
Control MMR (n ¼ 6) (PBS day 3) 0.00 ± 0.00 0.00 ±
Early treated (n ¼ 7) (UC-MSC day 3) Day 56 0.00 ± 0.00 0.00 ±
Delayed treated (n ¼ 7) (UC-MSC day 15) 8.57 ± 9.00 4.29 ±
(*P < 0.05).MSC injected synovium. The other studied parameters were
considered within normal range. At day 56, synovial lympho-
plasmacytic inﬁltrate is still present in both UC-MSC treated
groups, along with a moderate increase of the synovial cellularity
and vascularization. No neutrophilic inﬁltrations were observed.
Data are summarized in Table III.
EPIC-mCT
A trend toward lower values of the distribution of thickness was
observed in operated rabbits compared to normal range though the
difference was not signiﬁcant (Annex 4). No signiﬁcant difference
was observed between operated groups. These results conﬁrmed
the mild stage of OA obtained with this model concerning the
cartilage volume.
Analysis of synovium and cartilage gene expression
OA synovium gene expression analysis
The effects of early or delayed IA injection of UC-MSC on the
synovial inﬂammatory and catabolic responses were investigated
by qPCR.
At day 15 [Fig. 3 (A)], early injection of MSC (d3; n¼ 7) induced a
signiﬁcant up-regulation of TNF-a (6-fold, P ¼ 0.002), compared to
control-operated group (n ¼ 6). IL1-b was up-regulated by
approximately 2.5-fold. The anti-inﬂammatory cytokine IL10 was
signiﬁcantly over-expressed in the early group (1.6-fold, P ¼ 0.03).
Moreover, IL4 was undetectable in 4/6 samples from the control-
operated group (Ct > 45) while IL4 expression was measured in
all samples from the UC-MSC treated group (mean Ct values ¼ 35,
SD ¼ 2.6; results were conﬁrmed on agarose gel). Interestingly, the
highest Ct values were obtained in the samples exhibiting the
highest lymphoplasmacytic inﬁltrate scores. The expression of the
matrix-degrading enzymes (MMP-1, -3, -13) was not affected by
cell injection.
At the end point of the study (d56), we observed an overall
down-regulation of the mRNA levels of MMPs, TNF-a, and IL1-b in
both early and delayed treatment groups compared to control-group had a signiﬁcantly lower VAE score in the medial tibial condyle cartilage than
ations (mean ± SD)
Tibial condyles Femoral trochlea Patella
l Medial Lateral
0.00 11.79 ± 7.32 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.00 28.33* ± 9.04 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.00 10.00 ± 5.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
7.87 30.36* ± 13.57 2.86 ± 4.88 0.00 ± 0.00 0.00 ± 0.00
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MSC injection modulates the gene expression of the inﬂammatory
cytokines and the matrix-degrading enzymes. To understand if the
timing of injection played a signiﬁcant role in the synovial
response, analysis was further focused on early (n ¼ 7) vs delayed
(n ¼ 7) treatment group comparison [Fig. 3(B)]. A global down-
regulation of the expression of the three MMPs (~3.5-fold
decrease), along with reduced level of TNF-a mRNA levels (~3-
fold decrease) were observed in the early treatment group
compared to the delayed treatment group. No difference was
observed for IL1-b and IL10 mRNA levels. The expression of the
tissue inhibitor of metalloproteinase 1 (TIMP1) was similar in both
cell-treated groups (data not shown).
Cartilage gene expression analysis
Gene expression of the chondrogenic genes COL2a and ACAN
was investigated in cartilage specimens collected at d56 from early
and delayed treatment groups. qPCR analysis showed increased
expression of COL2a in the early treatment group (~2-fold increase;
P ¼ 0.05), while ACAN expression was similar. No difference was
observed for the hypertrophic chondrocyte marker COL10. Results
are illustrated in Fig. 4.
In vitro model of MSC/synovium interactions
UC-conditioned medium decreased the expression of MMP-1
(~6-fold decrease), MMP-3 (~7-fold decrease) and MMP-13 (~8-
fold decrease, P ¼ 0.03) in comparison to standard proliferation
medium. The expression of IL1-b was signiﬁcantly down-regulated
(~25-fold decrease, P ¼ 0.009), while the expression of TNF-a was
not changed. The levels of TIMP1 mRNA were also modestly
reduced (~2-fold decrease, P ¼ 0.04) probably as a regulatory
mechanism (Fig. 5). These data show an overall decrease of the
expression of pro-inﬂammatory and catabolic genes in synovio-
cytes cultured in UC-conditioned medium.
Discussion
In the present study, we evaluated the efﬁcacy of early or
delayed IA injection of xenogeneic UC-MSC to counteract synovial
inﬂammation and prevent articular cartilage lesions in a rabbit
model of mild OA. The model was chosen to mimic the onset of the
disease, as assessed by slight but reproducible OA tissue changes.
From a clinical point of view, neither severe adverse effects nor
acute immune rejection were observed following the xeno-
transplantation. The major ﬁnding is that at end-point evaluation,
UC-MSC injected rabbits showed a persistent synovial reactivity
and reduced cartilage alterations when treated early.
Targeting the synovial tissue for OAmanagement has become an
attractive therapeutic option. Here, we reported that xenogeneic
UC-MSC transplantation induced prolonged morphological
changes in synovium, along with a signiﬁcant molecular response
of inﬂammatory and catabolic genes. Lymphoplasmacytic in-
ﬁltrates were identiﬁed in the synovium of UC-MSC groups by 2
weeks post-injection that were still present at the end-point of the
study (d56). This data corroborates a recent publication in horses in
which IA injection of MSC, regardless of cell origin (autologous,
allogeneic, or xenogeneic), was shown to produce a persistent
mononuclear inﬁltrate for at least 60 days in the synovium16. Thus
IA injection of xenogeneic MSC induces a consistent local recruit-
ment of endogenous cells in the synovium, which might relay MSC
action and induce a persistent effect. Molecular analysis conﬁrmed
the strong reactivity of synovial tissue to UC-MSC transplantation.
Two weeks post-surgery, MSC exerted both pro- (IL1-b, TNF-a) and
anti- (IL4, IL10) inﬂammatory cytokines up-regulation. IL4 and IL10
Fig. 3. Gene expression analysis of synovial tissue from control-operated and cell-treated rabbits. (A) Boxplot representations of the early time point analyses of synovial tissue
(d15). “Control” represents MMR-operated animals (n ¼ 6), “Early” represents animals injected with MSC at day 3 (n ¼ 6) (one sample has been excluded because of low yield and
poor quality of RNA following extraction). (B) Boxplot representations of the late time point analyses of synovial tissue (d56). “Early” represent animals injected with MSC at day 3
(n ¼ 7), “delayed” represent animals injected with MSC at day 15 post-surgery (n ¼ 7) (*P<0.05). The box borders represent the interquartile range and the horizontal thick line in
the box is the median. “” indicates an outlier.
N. Saulnier et al. / Osteoarthritis and Cartilage 23 (2015) 122e133128are regulatory mediators produced by activated macrophages and
Th2 lymphocytes with the potential to antagonize inﬂammation
and counteract the degenerative process. Marked protection of
cartilage has been reported with IL4/IL10 treatment in several
preclinical models of collagen-induced arthritis31,32. Interestingly,
in our study, higher levels of IL4 mRNA were measured in the
samples displaying the highest lymphoplasmacytic inﬁltrates
scores (data not shown). This data suggests that cell inﬁltrates mayhave been polarized toward a Th2-type response and contribute to
the local immunomodulation. Previous work reported that human
MSC exhibit an immune-suppressive effect on rabbit lymphocytes
in vitro and modulate the immune response in the host system
in vivo20. The inhibitory effect of xenogeneic MSC on the lympho-
cyte response was even stronger compared with autologous MSC.
Altogether, these data suggest that the synovial response may be
inﬂuenced by xenogeneic MSC.
Fig. 4. Gene expression analysis of cartilage sections from early (n ¼ 7) and delayed treated (n ¼ 7) animals at d56 (*P<0.05).
N. Saulnier et al. / Osteoarthritis and Cartilage 23 (2015) 122e133 129By 2 months post-surgery, attention was paid to compare the
efﬁciency of early (d3) or delayed (d15) injection of UC-MSC in the
OA onset. Molecular analysis of synovial tissue showed a trend for
decreased levels of MMP-1, -3, and -13 mRNA in the early treat-
ment group. These proteases are key regulators of cartilage
destruction. Among them, MMP-13 is speciﬁcally up-regulated in
patients with OA, and a correlation has been established betweenFig. 5. Gene expression analysis in synoviocytes cultured under proinﬂammatory con
“Conditioned” (*P<0.05).the synovial MMP-13 expression and cartilage degeneration33. We
observed the same link between the MMP-13 level and the
articular cartilage lesions. Indeed macroscopic cartilage alterations
were reduced in the early treatment group, while the expression
of the chondrocytic marker COL2a was up-regulated. Altogether,
these data show that UC-MSC exert biphasic effects on synovial
tissue, modulating the inﬂammatory response and reducing thedition (IL1-b/48 h) in standard medium “Control” and UC-conditioned medium
N. Saulnier et al. / Osteoarthritis and Cartilage 23 (2015) 122e133130catabolic process in OA onset. Our data also showed that delivery
of UC-MSC early following the induction of OA slows down
articular cartilage degradation more efﬁciently. Indeed, MSC are
clinically effective during a narrow window of time following
experimental injury34.
Although paracrine signaling is considered as the main mech-
anism by which MSC promote tissue regeneration35, it remains
unclear which factors are involved especially in a xenogeneic
setting. In an in vitro model of rabbit primary synoviocyte cultures
stimulatedwith IL1-b and incubatedwith UC-conditionedmedium,
we showed a trend toward a down-regulation of inﬂammatory and
catabolic genes similarly towhat was observed in ex vivo synovium.
In our model, we used UC-conditioned medium collected from
non-stimulated MSC cultures. Recently van Buul et al. reported that
MSC required in vitro priming to exert anti-inﬂammatory effects on
osteoarthritic synovium36. The discrepancy between our results
and their data suggests that the origin of MSC (neonatal vs adult)
could inﬂuence the properties of the cells. Further analyses of the
factors secreted by each MSC population will help to evaluate their
therapeutic interest.
Conclusion
This study shows the efﬁciency of a single IA injection of
xenogeneic UC-MSC in preventing OA signs in rabbits following
MMR. Early IA injection might be more efﬁcient in reducingGene name Symbol Forward sequence Reverse sequence
Interleukin 1 beta Il1-b TACAACAAGAGCTTCCGGCA GGCCACAGGTATCTTGTCGT
Tumor Necrosis Factor alpha TNF-a CGTAGTAGCAAACCCGCAAGTGGA TTGTTCGGGTAGGAGACGGCGA
Interleukin 4 IL4 CGACATCATCCTACCCGAAGTC CCTCTCTCTCGGTTGTGTTCTTG
Interleukin 10 IL10 CTTTGGCAGGGTGAAGACTTTC AACTGGATCATCTCCGACAAGG
Matrix Metalloproteinase 1 MMP-1 CCTGATGTGGCTCAGTTCGT GTCCACATCTGCCCTTGACA
Matrix Metalloproteinase 3 MMP-3 ACACCGGATCTGCCAAGAGA CTGGAGAACGTGAGTGGAGTCA
Matrix Metalloproteinase 13 MMP-13 AGTCTCCAGGCACGGCCATT GGTAGCTCTCTGCAAACTGGAAGTC
Tissue Inhibitor of Metalloproteinase 1 TIMP1 GGACAGACCAGCTCCTCCTA TAGGCTTCGGCTTCCAACAG
Collagen 2a COL2a TGAAGACACCAAGGACTGCC GCAGTGGCGAGGTCAGTAG
Aggrecan ACAN GCCTTTCAAGCCCTTGTGTG CTCCTCACAGACCTCCTGGT
Collagen 10 COL10 GCCCACAACCCAACACCAAGAC GCCCAATGTCTCCTTTCGGTCCA
Hypoxanthine-guanine phosphoribosyltransferase HPRT TGATAGATCCATTCCTATGACTGTAGA GGGTCCTTTTCACCAGCAGinﬂammation and preventing OA progression than delayed injec-
tion. More speciﬁcally, our study conﬁrms that MSC produce
bioactive molecules that function across barrier species and
modify genes related to inﬂammation and matrix turnover in
synoviocytes. The recruitment of endogenous cells might partici-
pate in the local immune modulation and restore a favorable
environment. Conclusions drawn on the basis of xenorecipient
models have to be taken with caution, as immune response should
be exacerbated in this setting. Nonetheless, such in vivo models
are useful to study the interactions of MSC with their
microenvironment.Contributions
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ANNEXES
Annex 1
Primer nucleotide sequences.Annex 2
Representative ﬂow cytometric proﬁles of UC-MSC. UC-MSC
were uniformly CD44þ, CD90þ, MHC1þ, CD29þ, CD105þ, while no
expression of CD45 and MHC2 was detected. Dashed lines
represent negative isotype control staining, grey ﬁlled histograms
represent samples incubated with the indicated antibody.Annex 3
Representative pictures of cytochemical analyses of differenti-
ation assays. A: Osteogenic differentiation assessed by alizarin red
staining (A1: Unstimulated UC-MSC/A2: UC-MSC cultured 2 weeks
in osteogenic medium; Magniﬁcation: 40). B: Adipogenic differ-
entiation detected by staining of lipid droplets by O red oil (B1:
Unstimulated UC-MSC/B2: UC-MSC cultured 2 weeks with adipo-
genic medium; Magniﬁcation: 200). C: Chondrogenic differenti-
ation visualized by Alcian blue staining. (C1: Unstimulated UC-
MSC; C2: UC-MSC cultured 2 weeks with chondrogenic medium;
Magniﬁcation: 100).
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N. Saulnier et al. / Osteoarthritis and Cartilage 23 (2015) 122e133132Annex 4
EPIC-mCT analyses. Comparison of the distribution thickness of
the medial tibial condyle cartilage in control and operated knees 8
weeks after surgery. The large standard deviation in the high values
was expected as it is due to interindividual variations.References
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